Roberto Guerra
Payments from drug & device makers
Across 427 payments — averaging $24.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Teva Pharmaceuticals USA, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Johnson & Johnson$915
- Alkermes, Inc.$911
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$785
- plus $3K from 16 others
What the payments were for
- Food & beverage$10,614100%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 100 | $2,518 |
| Teva Pharmaceuticals USA, Inc. | 44 | $1,290 |
| Otsuka America Pharmaceutical, Inc. | 50 | $1,121 |
| Johnson & Johnson | 41 | $915 |
| Alkermes, Inc. | 35 | $911 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 34 | $785 |
| Indivior Inc. | 24 | $684 |
| Lundbeck LLC | 20 | $467 |
| Vanda Pharmaceuticals Inc. | 16 | $432 |
| Axsome Therapeutics, Inc. | 18 | $421 |
| Idorsia Pharmaceuticals US Inc | 12 | $341 |
| E.r. Squibb & Sons, L.L.C. | 8 | $282 |
| Almatica Pharma LLC | 4 | $83 |
| Bausch Health US, LLC | 5 | $81 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $81 |
| Luye Pharma (USA) Ltd. | 4 | $76 |
| Neurocrine Biosciences, Inc. | 2 | $45 |
| Merck | 2 | $27 |
| Noven Therapeutics, LLC | 1 | $19 |
| Pfizer | 1 | $18 |
| Acadia Pharmaceuticals Inc | 1 | $18 |
| Adlon Therapeutics L.p. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,627 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Quetiapine Fumarate | 20 | $276 |
| Pantoprazole Sodium | 18 | $195 |
| Gabapentin | 11 | $159 |
| Risperidone | 11 | $105 |
| Atorvastatin Calcium | 17 | $84 |
| Famotidine | 11 | $65 |
| Hydrochlorothiazide | 11 | $59 |
| Amlodipine Besylate | 15 | $56 |
| Trazodone Hcl | 13 | $34 |
Paid to pharmacies, not to this prescriber.
Other family in Miami
- Stephanie MompointMiami$4.5M
- Itsel Cardenas RamonMiami$1M
- Patrick SzarazMiami$327K
- Yamila MelendezMiami$212K
- Suzan RosenMiami$129K
- Felipe NovoaMiami$110K
- Pamela DudkiewiczMiami$89K
- Stacy FeemsterMiami$51K
- John HuffakerVenice$8M
- Miguel TrujilloMiami Gardens$4.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.